



Docket No.: 1056-0135PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	Patent Application of: ohiro MATSUSHIMA et al.	
Appli	ication No.: 10/577,065	Confirmation No.: 9862
Filed	: April 24, 2006	Art Unit: N/A
For:	NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1)	Examiner: Not Yet Assigned
F	RESPONSE TO NOTIFICATION TO COMPONION OR PATENT APPLICATIONS CONTAINING ACID SEQUENCE DISCI	NUCLEOTIDE AND/OR AMINO
Comr P.O.	Missing Parts missioner for Patents Box 1450 andria, VA 22313-1450	
Sir:		
	In response to the Notification to Comply with aining Nucleotide and/or Amino Acid Sequencicant respectfully submits:	
⊠ Appli	Attached is a copy of the Notification to Cications Containing Nucleotide and/or Amino Acid S	
	Under the provisions of 37 C.F.R. §§ 1.41(c) and Declaration of the inventor(s) (original philling requirements in connection with the above-in	notocopy), necessary for completing the

Appli	cation No.: 10/577,065	Docket No.: 1056-0135PUS1
	Declaration that was attached to the specification is a true copy of the specific	(c) and 1.53(f), attached hereto is the executed fication at the time of execution. The attached fication that was filed in the U.S. Patent and merica, including any amendments thereto (if
	of the attached inventors' Declaration,	orney Docket No. 1056-0135PUS1" on page 1 corresponds to Appl. No. 10/577,065, filed DINE DERIVATIVE AND PYRIMIDINE
		n of the above-identified application that was e used as the copy for examination purposes.
	See the attached Translator's Verific	ation; or
	_	glish translation attached hereto is a true and as originally filed in a foreign language.
	Attached are 0 sheet (s) of drawings. Please corresponding 0 sheet(s) of drawings on file	e substitute these replacement drawings for the in the above-identified application.
\boxtimes	Attached is an Amendment.	
	Attached is paper copy of the Sequence Listing.	Listing and CRF disk copy of the Sequence
	Attached is a substitute abstract commence C.F.R. § 1.72(b).	ng on a separate sheet in accordance with 37
	Attached is a substitute specification that of specification does not contain new matter.	omplies with 37 C.F.R. § 1.52. The substitute

MSW/sh

Docket No.: 1056-0135PUS1 Application No.: 10/577,065 Applicant claims small entity status under 37 C.F.R. § 1.27. Attached is a Claim for Priority document. Attached is a Supplemental Application Data Sheet (ADS). Submitted concurrently herewith under separate cover for recording is an Assignment. Attached is a Petition for Extension of Time. Attached hereto is the fee transmittal listing the required fees. If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees. Respectfully submitted, Dated: MAR 8 2007 Marc S. Weiner Registration No.: 32,181 BIRCH, STEWART, KOLASCH & BIRCH, LLP 8110 Gatehouse Road Suite 100 East P.O. Box 747 Falls Church, Virginia 22040-0747 (703) 205-8000 Attorney for Applicant

Attachment(s)

3 MSW/sh



United States Patent and Trademark Office

MAR 0 8 2007

vog.odqsu.www

TATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vinninia 22313-1450

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

ATTY, DOCKET NO.

10/577,065

Tomohiro Matsushima

1056-0135PUS1

INTERNATIONAL APPLICATION NO.

PCT/JP05/03701

2292 **BIRCH STEWART KOLASCH & BIRCH** PO BOX 747 FALLS CHURCH, VA 22040-0747

FAUTHOR

PRIORITY DATE J.A. FILING DATE 02/27/2004 02/25/2005

CONFIRMATION NO. 9862 371 FORMALITIES LETTER *OC000000021878441*

Date Mailed: 01/08/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR, 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

KAYA L LEWIS BALTIMORE

Telephone: (703) 308-9140 EXT 202

PART 1 - ATTORNEY/APPLICANT COPY

INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.	
PCT/JP05/03701	1056-0135PUS1	
	INTERNATIONAL APPLICATION NO. PCT/JP05/03701	

FORM PCT/DO/EO/922 (371 Formalities Notice)